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Summary
Mice with interleukin (IL)-7 transgene under the control of E α promoter over-express IL-7 in MHC class II-positive cells and develop specific immune phenotype, marked by an increase in CD45R + cells in both the bone marrow and peripheral blood. We show that IL-7 transgenic mice have a bone phenotype characterized by an age-related loss of trabecular bone in both axial and long bones. Osteopenia was the result of increased number of active osteoclasts on the surface of trabecular bone. Furthermore, IL-7 transgenic mice showed increased osteoclastic but unchanged osteoblastic potential of the bone marrow in vitro. IL-7 overexpression also created osteoclastogenic microenvironment within the bone marrow which promoted the commitment of precursors towards the osteoclast lineage. These findings are important for immunological disturbances where IL-7 is involved and where alterations in the immune system are accompanied by changes in bone metabolism, such as multiple myeloma, rheumatoid arthritis and postmenopausal osteoporosis.
Introduction
Interleukin-7 (IL-7) is produced by thymic and bone marrow (BM) stromal cells and mediates critical steps during early T and B lymphocyte development in mice [1] . Transgenic mice over-expressing IL-7 under different promoters develop lymphoproliferative phenotype [2, 3] . IL-7 has been implicated in bone homeostasis, but its effects on bone cells are contradictory [4] [5] [6] . In vitro, IL-7 had inhibitory effect on both osteoclasts (OCL) [4] and osteoblasts (OBL) [6] . In vivo, young female transgenic mice expressing human IL-7 gene selectively in OBLs showed increased numbers of early B lymphocytes in the BM and increased trabecular bone mass [7, 8] . Mice expressing an IL-7 transgene driven by MHC class II (E α ) promoter [3] develop enlarged marrow cavity and focal osteolysis related to the lymphoproliferative phenotype [9] . Within the immune system, MHC class II molecules are constitutively expressed by stromal cells and antigen-presenting cells, and can be induced in other cells during immune response [10] . As the control of IL-7 production by MHC class II promoter mimics pathological states marked by prolonged stimulation of lymphocytes [10] , such as in autoimmune diseases, we assessed bone morphology and function in mice overexpressing IL-7 transgene driven by the MHC class II (E α ) promoter.
Materials and Methods

IL-7 transgenic mice
Male and female mice hemizygous for IL-7 transgene in C57BL/6 background (IL-7 TG mice) [3, 9] and wild-type (Wt) littermates were analyzed at 8 weeks, and 6 or 12 months of age. IL-7 transgene carriers were identified by PCR amplification [9] . Immune phenotype was confirmed by flow cytometry [11] .
Bone histomorphometry 
Bone cell cultures
BM cells from long bones were cultured in conditions stimulating either OCL [13] or OBL differentiation [14] . Briefly, BM cells were flushed out from long bones, washed, passed through a 40 µm pore size nylon cell strainer and resuspended in α-MEM supplemented with 10% fetal bovine serum (FBS; Hyclone, Logan, UT, USA).
For OBL cultures [14] , BM cells were seeded into 6-well plates and cultured at a concentration of 7×10 6 cells in 3 ml per well in α-MEM/10%FBS. On day 4 of culture medium was changed. On day 7 of culture, the medium was changed and supplemented with 8 mM β-glycerophopsphate, 10 -8 M dexamethasone and 50 µg/ml ascorbic acid. On day 11, cultures were fixed in 2% paraformaldehyde in PBS for 10 minutes and stained for alkaline phosphatase (AP) using a commercial kit (Sigma-Aldrich), and for mineralizing (Von Kossa 6 staining) or total fibroblast colonies (methylene blue staining). AP positive, mineralising or fibroblast colonies were counted in 3 wells per group for each experiment [14] .
For OCLic cultures [13] BM cells were incubated overnight with 5 ng/mL recombinant murine macrophage colony stimulating factor (rmM-CSF, R&D Systems, Abingdon, UK) in α-MEM/10%FBS to stimulate monocyte-macrophage lineage, followed by harvesting of nonadherent cells, enriched in noncommitted hematopoietic progenitors [13] . Non-adherent cells were seeded into a 48-well plate and cultured in α-MEM/10%FBS with 20 ng/mL of recombinant murine receptor activator of NF-κB ligand (rmRANKL) and 10 ng/mL of rmM-CSF, in the density of 0.5×10 6 cells in 0.5 mL. Medium was changed on day 3 of culture, and on day 6, the cultures were fixed with 2.5% glutaraldehyde in PBS for 30 minutes at room temperature and stained for TRAP, using a commercial kit (Sigma-Aldrich). TRAP-positive cells with ≥3 nuclei were considered OCLs [13] ; their functional activity was confirmed by their ability to resorb calcium phosphate films (BD Biosciences, San Jose, California, USA).
For co-culture experiments, the supernatants from Wt and IL-7 TG OCL cultures were collected at the end of the culture period (day 6) and frozen. Supernatants were added in a 25% final volume to new OCL cultures, together with α-MEM/10%FBS, rmRANKL and rmM-CSF, at day 1, and again at day 3 of culture.
Neutralization of IL-7 was performed by following a protocol for neutralization of soluble cytokines [13] . Briefly, supernatant from IL-7 TG OCL cultures was first incubated with neutralizing IL-7 antibody (R&D Systems) for 1 h at 37 ºC, and than added to Wt OCL cultures in a final volume ratio of 25%. The final concentration of anti-IL-7 antibody in the OCL culture was 2 µg/mL [4] . 
Gene expression analysis
Total RNA was extracted from cultured cells using a commercial kit (TriPure; Roche, Basel Switzerland). For PCR amplification, 2 µg of total RNA was converted to cDNA by reverse transcriptase (Applied Biosystems, Foster City, CA). The amount of cDNA corresponding to 20 ng of reversely transcribed RNA was amplified by qPCR, using specific amplimer sets and SYBR Green chemistry for β-actin, and TaqMan Assays and TaqMan chemistry for IL-7 and IL-7R (Applied Biosystems). Quantitative PCR was conducted using an ABI Prism 7000
Sequence Detection System (Applied Biosystems). Each reaction was performed in duplicate or triplicate in a 25 µL reaction volume. The generated data were analyzed by plotting the fluorescence signal ∆Rn vs. the cycle number. An arbitrary threshold was set on the linear phase midpoint of the log ∆Rn vs. cycle number plot. The cycle threshold (Ct) value was defined as the cycle number at which ∆Rn crossed this threshold. The expression of specific genes was calculated according to the standard curve of gene expression in the calibrator 8 sample (cDNA from control osteoclastogenic culture) and normalized to the expression of the gene for β-actin ("endogenous" control) [14] .
Statistical analysis
All values are expressed as mean ± standard error of the mean, and the groups were compared using ANOVA with Student-Newman-Keuls post hoc test. The α level was set at 0.05. All experiments were repeated at least three times and the data are from a representative experiment.
Results
Lymphoproliferative phenotype of IL-7 TG mice
Lymphoproliferative phenotype of IL-7TG mice [9] 
IL-7 TG mice have increased bone resorption in vivo and develop osteopenia
IL-7 TG mice developed marked osteopenia with age ( Fig. 1) . Decrease in the number and thickness of trabecular bone in long bones at 12 months ( Fig. 1 and 2 ) was preceded by vertebral trabecular bone loss already at 6 months of age (7.1±1.3% in IL-7 TG vs. (Fig. 1) . Trabecular bone loss in IL-7 TG mice was preceded by an increase in active OCL on metaphyseal and trabecular surfaces at 6 months, followed by increased OCLs at endoosteal surfaces at 12 months (Table 1) . (Table 2) , nor in number of mineralizing or total fibroblast colonies (data not shown).
BM microenvironment for increased osteoclastogenesis in IL-7 TG mice
Immune phenotype of IL-7 TG mice includes up to four-fold increase in CD45R + BM cells [9] , which may also have OCL differentiation potential in vitro [19, 20] . 
Discussion
Our study showed that systemic IL-7 over-expression linked to MHC class II expression induces not only the accumulation of B cells and its progenitors, but also OCL differentiation and subsequent trabecular bone loss in vivo. Bone loss was specific for trabecular bone, as the morphology of the epiphyseal growth plate was not affected. Bone trabeculae were decreased in number and thickness, enlarging the BM cavity.
The loss of bone in IL-7 TG mice was the consequence of increased number of OCL on trabecular and endoosteal surfaces. These findings demonstrated that the primary target of IL-7 over-expression in vivo was bone resorption, regardless of the underlying cause of overexpression, because findings in the IL-7 over-expression in MHC class II cells was similar to that in other in vivo models, such as treatment of intact mice with IL-7 or in IL-7 receptor (IL-7R) knockout mice [5] . Increased osteoclastogenesis as direct cause of bone loss was confirmed by demonstrating that BM cells from IL-7 transgenic mice formed more functional
OCLs in vitro than BM of age-and sex-matched Wt mice. Alterations in the osteoclastogenic potential were at least in part age-related because increased osteoclastogenesis was not evident in IL-7 TG mice before 6 months of age, and only 12 month old TG animals presented a fully developed bone phenotype.
Although bone loss is often caused by disturbances in both bone formation and resorption, IL-7 over-expression by MHC class II cells did not affect OBL differentiation, contrasting reports from other IL-7 over-expression models, such as inhibition of new bone formation by IL-7 in neonatal calvarial organ cultures [6] . Increase in OCL progenitor pool was not the only mechanism mediating the effect of IL-7 over-expression in the BM, as the differentiation stimulus could be transfered in vitro by humoral factors from transgenic OCL cultures. Furhermore, the finding that IL-7 specific antibody could not fully abrogate the effect of supernatant transfer demonstrated that IL-7 is not the sole mediator of increased osteoclastogenesis in IL-7 TG mice, but rather its 13 interactions with the whole BM microenvironment. This is in line with the proposal that IL-7 effects on bone cells depend on whether IL-7 is delivered systematically or locally [17] .
BM microenvironment plays a fundamental role in haematopoiesis, especially of B lymphocytes [22] . IL-7 over-expression may change BM microenvironment to promote differentiation of CD45R + cells along OCL pathway, as well as to secrete yet unidentified soluble osteoclastogenic factors in CD45R -BM populations. IL-7 has been shown to stimulate cytokine secretion from IL-7R-expressing BM stromal cells [22] . Another downstream cytokine in IL-7 over-expressing environment could be RANKL, the key osteoclastogenic factor that binds to its RANK receptor on OCL precursors [15] and is able to induce CD45R + cell proliferation in combination with IL-7 [23] . RANKL, shown to increase with IL-7 stimulation of T lymphocytes [15] , mediates bone resorption together with tumor necrosis factor-α in IL-7 treated mice [18] . As we added soluble RANKL and M-CSF in culture, the contribution of increased RANKL expression in stromal cells or T lymphocytes could not be assessed. Also, we could not use the experimental models withe exogeously added IL-7 to test cell responses to excess IL-7 as IL-7 protein is already over-expressed and secreted in vivo and in vitro in IL-7 TG mice [3] . Our future research focuses on the identification of factors in the BM microenvironment in IL-7 TG mice and their relationship to CD45R + cell population.
In conclusion, systemic over-expression of IL-7 in MHC class II positive cells caused a specific bone phenotype in which CD45R + population, expanded by IL-7 over production, could serve as OCL precursors and stimulate production of soluble factors to increase the osteoclastogenic potential of BM cells. These findings are important for immunological disturbances where IL-7 is involved and where alterations in the immune system are 14 accompanied by changes in bone metabolism, such as multiple myeloma, rheumatoid arthritis and postmenopausal osteoporosis [6, 24] . 
